Ensuring the safety and efficacy of GLP-1 drugs: How mass spectrometry powers the next wave of metabolic therapeutics

Therapeutic peptides, as well as broader biologics and biotherapeutics, are rapidly reshaping the treatment landscape for chronic diseases, offering precision, potency and specificity that small molecules often can’t match. Among peptide-based therapeutics, such as, Glucagon-Like Peptide-1 (GLP-1) receptor agonists – including semaglutide and liraglutide – have emerged as game changers in managing type 2 diabetes,… The post Ensuring the safety and efficacy of GLP-1 drugs: How mass spectrometry powers the next wave of metabolic therapeutics appeared first on Drug Discovery and Development.

Continue reading →